Hopefully the catchy title means more than just what we were shown with "target modulation" on slide 19 of the BIO CEO Feb 2017 conference. The data on that slide that shows mRNA changes of five targets (MYC, BCL2, CCR1, IL1RN, GPR183) from blood samples of patients treated with ZEN-3694. However, this data was not coupled with any direct measure of prostate cancer clinical activity.

As shown on slide 17 of that same presentation, secondary endpoints of this trial include measures of "preliminary clinical activity" including the prostate cancer working group 2 (PCWG2) criteria of prostate-specific antigen (PSA) response rate, radiographic response rate, progression-free survival (PFS), as well as circulating tumor cell (CTC) response rate. 

So hopefully the catchy title and "clinical validation" content of this abstract will include some of these secondary endpoint measures of clinical activity coupled with their whole blood pharmacodynamic marker assay.

BTW, the notification of abstract acceptance was sent out the day after this BIO CEO presentation in February. The abstract embargo is lifted on March 31. So the full text of the abstract won't be known until the day before the AACR conference begins (April 1).